| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284348 | Clinical Gastroenterology and Hepatology | 2009 | 7 Pages |
Abstract
In patients with CHC who did not respond to interferon-based regimens, higher doses of albinterferon had significant early antiviral activity and a low incidence of adverse events, with the types of adverse events similar to those observed with interferon.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
David R. Nelson, Vinod Rustgi, Vijayan Balan, Mark S. Sulkowski, Gary L. Davis, Andrew J. Muir, Louis R. Lambiase, Rolland C. Dickson, Russell H. Weisner, Michele Fiscella, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian,